Revenue Breakdown
Composition ()
No data
Revenue Streams
Bausch Health Companies Inc (BHC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Bausch & Lomb / International segment, accounting for 47.8% of total sales, equivalent to $1.28B. Other significant revenue streams include Salix and International Rx. Understanding this composition is critical for investors evaluating how BHC navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Bausch Health Companies Inc maintains a gross margin of 62.59%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 26.74%, while the net margin is 6.75%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively BHC converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BHC competes directly with industry leaders such as BRBR and CRON. With a market capitalization of $2.18B, it holds a significant position in the sector. When comparing efficiency, BHC's gross margin of 62.59% stands against BRBR's 29.13% and CRON's 49.47%. Such benchmarking helps identify whether Bausch Health Companies Inc is trading at a premium or discount relative to its financial performance.
